High Quality Dabigatran Etexilate Mesylate Factory Direct Sale CAS: 872728-81-9

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: White Powder
• Purity: >99%
• Model NO.: Frazer-Dabigatran Etexilate Mesylate
• Appearance: White Powder
• Shelf Life: 2 Years
• Storage: Store in a Well-Closed Container Away From Moistur
• Delivery: Express 5-7 Days Arrive
• Test Method: HPLC
• Assay: 99%
• MOQ: 1kg
• CAS: 872728-81-9
• Mf: C34h41n7o5.CH4o3s
• MW: 723.84
• Product Name: Dabigatran Etexilate Mesylate
• Transport Package: Foil Bag
• Specification: 99%
• Trademark: Xi′an Frazer Biotech Co., Ltd.
• Origin: China
• Production Capacity: 200kg Per Month

Product Description

High Quality Dabigatran Etexilate Mesylate Factory Direct Sale CAS: 872728-81-9

Specification of Analysis

Item	Specification
Specific rotation	+39.5 to +41.5°
State of solution(transmittance)	Clear 98.0% min.
Chloride[cl]	0.020% max.
Ammonium [NH4]	0.02% max.
Sulfate[SO4]	0.020% max
Iron[Fe]	10ppm max.
Heavy metals [Pb]	10ppm max
Arsenic[As2O3]	1ppm max
Other amino acids	Chromatographically not detectable
Loss on drying	0.20% max.
Residue on ignition[sulfated]	0.10% max.
Assay	99.0% min

 

Dabigatran etexilate mesylate is a direct thrombin inhibitor used in clinical practice and a new type of oral anticoagulant. Its mechanism of action is to inhibit the formation of fibrin through reversible and strong competition to bind to the specific binding site of thrombin fibrin, thereby inhibiting the formation of thrombus.
Dabigatran etexilate mesylate is a raw material for the blood system; an anticoagulant drug; it can be used in patients with non-valvular atrial fibrillation to reduce the risk of stroke and systemic embolism; Chemicalbook dabigatran etexilate is a new type of synthetic The direct thrombin inhibitor is a prodrug of dabigatran and is a non-peptide thrombin inhibitor.

Function
Dabigatran is used to prevent strokes in those with atrial fibrillation not caused by heart valve issues, as well as deep vein thrombosis and pulmonary embolism in persons who have been treated for 5-10 days with parenteral anticoagulant (usually low molecular weight heparin), and to prevent deep vein thrombosis and pulmonary embolism in some circumstances.
It appears to be as effective as w'arfarin in preventing nonhemorrhagic strokes and embolic events in those with atrial fibrillation not due to valve problems.

Service we can provide: 
1. Any inquiries will be replied within 24 hours.
2. Dedication to quality, supply & service.
3. Strictly on selecting raw materials.
4. OEM/ODM Available.
5. Reasonable & competitive price, fast lead time.
6. Sample is available for your evaluation & formulation development.